Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Cholinergic Markers (CHOLINE)

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Cell signaling
Use
Pharmacodynamic/response
Predictive
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

The investigators's objective is to prospectively explore the predicting value of CSF acetylcholine (Ach) and acetylcholinesterase activity (AchE-a) levels on cholinesterase inhibitors (ChEIs) response in AD patients.

Target Population/ Population Being Studied

Patients with AD

Length of Current Trial
6 months
Number of Trial Participants

100

Estimated Trial Completion
May 2021
What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physician who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Assistance Publique - Hôpitaux de Paris

“Cholinergic Markers Alzheimer's Disease (CHOLINE).” ClnicalTrials.gov. October 9, 2019. https://clinicaltrials.gov/ct2/show/NCT03090854?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&draw=3&rank=22